Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biotie Therapies Corp.

http://www.biotie.com/

Latest From Biotie Therapies Corp.

Will Mifepristone Be Recalled If Texas Ruling Remains In Effect? Biopharma Leaders Back FDA

It is ‘up in the air’ what manufacturers and the FDA will have to do if an appeals court does not stay the injunction against mifepristone. More than 400 biopharma industry leaders sign a letter calling for reversal of Judge Kacsmaryk’s order and supporting the FDA’s regulatory authority.

FDA Legal Issues

Scrip Asks…What Does 2023 Hold For Biopharma? Part 7: Clinical Trial Trends

From synthetic data to real-world data, from patient engagement to patient stratification, from combination trials to master protocols and from fully decentralized through hybrid to onsite trials, the world of clinical development is undergoing major changes. Fifty executives share their predictions around clinical trial trends for the year ahead.

Scrip Asks Clinical Trials

Financing Quarterly Statistics, Q4 2022

During Q4, biopharmas brought in an aggregate $17.5bn in financing and device company fundraising totaled $1.9bn; while in vitro diagnostic firms and research tools players raised $848m.

Deals BioPharmaceutical

Finance Watch: Fundraising Shows Preference For Later-Stage Companies

Recent financings, including the $150m launch of Pathalys and a planned $100m IPO for Mineralys, illustrate the reality of biopharma funding in 2023 – that having near-term clinical trial milestones are key to fundraising this year. Companies with dwindling cash are conserving the funds they have left.

Financing Business Strategies
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Other Names / Subsidiaries
    • Elbion GmbH
    • Synosia Therapeutics, Inc.
UsernamePublicRestriction

Register